Findings

What do systematic reviews say?

213 questions · 229 findings · 30 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 43 · 18.8%GRADE not reported 17 · 7.4%Very low 42 · 18.3%Low 67 · 29.3%Moderate 54 · 23.6%High 6 · 2.6%

MTX treated vs no MTX treated

Partial remission ( · Patients with AS

The review found no eligible studies for this question.

1 finding from 1 review

Methotrexate for ankylosing spondylitis 2013 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

MTX treated vs no MTX treated

BASFI (score from 0 to 10, 0=excellent, 10=poor function) · Patients with AS

1 finding from 1 review

Methotrexate for ankylosing spondylitis 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 35 participants
Low

MTX treated vs no MTX treated

X‐Ray of the spine · Patients with AS

The review found no eligible studies for this question.

1 finding from 1 review

Methotrexate for ankylosing spondylitis 2013 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

MTX treated vs no MTX treated

MRI · Patients with AS

The review found no eligible studies for this question.

1 finding from 1 review

Methotrexate for ankylosing spondylitis 2013 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

MTX treated vs no MTX treated

Serious adverse event · Patients with AS

The review found no eligible studies for this question.

1 finding from 1 review

Methotrexate for ankylosing spondylitis 2013 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

MTX treated vs no MTX treated

Withdrawals due to any reason · Patients with AS

MTX treated showed no clear difference in withdrawal for any reason compared with no MTX treated (low certainty).

1 finding from 1 review

Methotrexate for ankylosing spondylitis 2013 · Cochrane Headline outcomes only
RR 1.06 [0.07, 15.62]
1 study · 35 participants
Low

MTX combination vs MTX monotherapy

ACR 50 response of DMARDs naive patients Number of responders · patients with rheumatoid arthritis

MTX combination showed no clear difference in ACR 50 response of DMARDs naive patients Number of responders compared with MTX monotherapy (low certainty).

1 finding from 1 review

Methotrexate monotherapy versus methotrexate combination therapy with non‐biologic disease modifying anti‐rheumatic… 2010 · Cochrane Headline outcomes only
RR 1.76 [0.64, 4.85]
2 studies · 127 participants
Low

MTX combination vs MTX monotherapy

ACR 50 response of MTX inadequate responders number of responders · patients with rheumatoid arthritis

MTX combination probably leads to higher ACR 50 response of MTX inadequate responders number of responders compared with MTX monotherapy (moderate certainty).

1 finding from 1 review

Methotrexate monotherapy versus methotrexate combination therapy with non‐biologic disease modifying anti‐rheumatic… 2010 · Cochrane Headline outcomes only
RR 4.54 [2.51, 8.2]
3 studies · 404 participants
Moderate

MTX combination vs MTX monotherapy

ACR 50 response of non‐MTX DMARDs inadequate responders number of responders · patients with rheumatoid arthritis

MTX combination showed no clear difference in ACR 50 response of non‐MTX DMARDs inadequate responders number of… compared with MTX monotherapy (moderate certainty).

1 finding from 1 review

Methotrexate monotherapy versus methotrexate combination therapy with non‐biologic disease modifying anti‐rheumatic… 2010 · Cochrane Headline outcomes only
RR 1.68 [0.94, 2.99]
2 studies · 158 participants
Moderate

MTX combination vs MTX monotherapy

Withdrawal due to lack of efficacy or toxicity of DMARDs naive patients number of withdrawals · patients with rheumatoid arthritis

MTX combination showed no clear difference in withdrawal due to lack of efficacy or toxicity of DMARDs naive… compared with MTX monotherapy (moderate certainty).

1 finding from 1 review

Methotrexate monotherapy versus methotrexate combination therapy with non‐biologic disease modifying anti‐rheumatic… 2010 · Cochrane Headline outcomes only
RR 1.16 [0.7, 1.93]
5 studies · 405 participants
Moderate

MTX combination vs MTX monotherapy

Withdrawal due to lack of efficacy or toxicity of MTX inadequate responders number of withdrawals · patients with rheumatoid arthritis

MTX combination showed no clear difference in withdrawal due to lack of efficacy or toxicity of MTX inadequate… compared with MTX monotherapy (moderate certainty).

1 finding from 1 review

Methotrexate monotherapy versus methotrexate combination therapy with non‐biologic disease modifying anti‐rheumatic… 2010 · Cochrane Headline outcomes only
RR 0.86 [0.49, 1.51]
3 studies · 476 participants
Moderate

MTX combination vs MTX monotherapy

Withdrawal due to lack of efficacy or toxicity of non‐MTX DMARDs inadequate responders number of withdrawals · patients with rheumatoid arthritis

It is very uncertain whether MTX combination changes withdrawal due to lack of efficacy or toxicity of non‐MTX DMARDs… compared with MTX monotherapy (very low certainty).

1 finding from 1 review

Methotrexate monotherapy versus methotrexate combination therapy with non‐biologic disease modifying anti‐rheumatic… 2010 · Cochrane Headline outcomes only
RR 0.75 [0.41, 1.35]
5 studies · 329 participants
Very low

MTX combination vs MTX monotherapy

Withdrawals due to adverse events · patients with rheumatoid arthritis

It is very uncertain whether MTX combination changes withdrawal due to adverse reactions (Pooled across regimens) number… compared with MTX monotherapy (very low certainty).

1 finding from 1 review

Methotrexate monotherapy versus methotrexate combination therapy with non‐biologic disease modifying anti‐rheumatic… 2010 · Cochrane Headline outcomes only
RR 1.59 [1.2, 2.12]
17 studies · 1624 participants
Very low